Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a commercial-stage biopharmaceutical company developing and commercializing therapies for chronic endocrine and neurological diseases, primarily for the U.S. market. Its marketed products are Recorlev, for adults with Cushing’s syndrome when surgery is not an option or… From the company’s description.
Over the twelve months to Sep 30, 2026, Xeris Biopharma Holdings, Inc. reported revenue of $368.26M, up 38.4% from a year earlier, and a net loss of $6.50M. Its operating margin was 12.7%, and operations generated $73.65M in cash. In fiscal 2025, it reported revenue of $291.85M, up 43.7% from fiscal 2024, and net income of $0.55M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Xeris Biopharma Holdings, Inc. does
In the company’s own words
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a commercial-stage biopharmaceutical company developing and commercializing therapies for chronic endocrine and neurological diseases, primarily for the U.S. market. Its marketed products are Recorlev, for adults with Cushing’s syndrome when surgery is not an option or has not cured the condition; Gvoke, a ready-to-use glucagon product for severe hypoglycemia in adults and children with diabetes aged two and older; and Keveyis, for primary periodic paralysis. Its pipeline includes XP-8121, a once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and it pursues formulation partnerships with pharmaceutical companies. Xeris’s proprietary XeriSol and XeriJect technologies are designed to produce stable, concentrated, ready-to-use injectable formulations; the company also licenses these technologies for development of other companies’ drugs and biologics. The business centers on its commercial products, pipeline and technology partnerships rather than separately reported operating segments. In 2025, revenue was $ million. The company acquired Keveyis through its acquisition of Strongbridge Biopharma. Its website is www.xerispharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1867096
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Xeris Biopharma Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Xeris Biopharma Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Xeris Biopharma Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Xeris Biopharma Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Xeris Biopharma Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”